Press releases
- Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
- Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
- Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
- Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
- Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
- Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
- Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
- Moleculin Reports Full Year 2023 Financial Results
- Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
More ▼
Key statistics
As of last trade, Moleculin Biotech Inc (0K2H:LSE) traded at 5.25, 22.56% above the 52 week low of 4.28 set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 5.25 |
Average volume | 201.20 |
---|---|
Shares outstanding | 2.23m |
Free float | 2.12m |
P/E (TTM) | -- |
Market cap | 11.47m USD |
EPS (TTM) | -15.06 USD |
Data delayed at least 20 minutes, as of May 02 2024 16:48 BST.
More ▼